Treatment of hepatitis B reinfection after liver transplantation

Minerva Chirurgica

Volumn 58, Issue 5, 2003, Pages 705-716

  Beckebaum, S ^a,b   Cicinnati, V R ^a   Gerken, G ^a   Broelsch, C E ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Hepatitis B vaccines; Hepatitis B, genetics; Immunoglobulins; Interferon alpha; Nucleosides

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CORTICOSTEROID; DNA POLYMERASE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TENOFOVIR; VIRUS DNA;

ANAPHYLAXIS; CHRONIC HEPATITIS; CLINICAL TRIAL; DIAGNOSTIC TEST; DNA SEQUENCE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; GENE MUTATION; GRAFT SURVIVAL; HAIR LOSS; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION; INFECTION PREVENTION; INSOMNIA; LEUKOPENIA; LIVER TRANSPLANTATION; MENTAL DISEASE; MERCURIALISM; NEPHROTOXICITY; NEUROLOGIC DISEASE; PATIENT MONITORING; POSTOPERATIVE CARE; PROTEIN MOTIF; REINFECTION; REVIEW; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS REPLICATION; WILD TYPE;

DRUG THERAPY, COMBINATION; HEPATITIS B; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INTERFERON-ALPHA; LAMIVUDINE; LIVER TRANSPLANTATION; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0347597082     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
2. Belle SH, Beringer KC, Murphy JB, Detre KM. The Pitt-UNOS Liver Transplant Registry. Clin Transpl 1992:17-32.
3. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002;235:611-20.
4. Eason JD, Freeman RB jr, Rohrer RJ, Lewis WD, Jenkins R, Dienstag J et al. Should liver transplantation be performed for patients with hepatitis B? Transplantation 1994;57:1588-93.
5. Jakobs JM, Martin P, Munoz SJ, Westerberg S, Hann HW, Moritz MJ et al. Liver transplantation for chronic hepatitis B in Asian males. Transplant Proc 1993;25:1904-6.
6. Lok ASF. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002;8:S67-73.
7. Wong PY, McPeake JR, Portmann B, Tan KC, Naoumov NV, Williams R. Clinical course and survival after liver transplantation for hepatitis B virus infection complicated by hepatocellular carcinoma. Am J Gastroenterol 1995;90:29-34.
8. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with postive hepatitis B core antibody. Liver Transpl 2002;8:556-61.
9. Prieto M, Gomez MD, Berenguer M, Cordoba J, Rayon JM, Pastor M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001;7:51-8.
10. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transplant 2002;8:S82-7.
11. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg 1998;4:128-32.
12. Chen YS, Wang CC, de Villa VE, Wang SH, Cheng YF, Huang TL et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transpl 2002;16:405-9.
13. Chazouilleres O, Mamish D, Kim M, Carey K, Ferell L, Roberts J et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994;343:142-6.
14. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-33.
15. Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998;227:841-50.
16. Steinmuller T, Seehofer D, Rayes N, Muller AR. Settmacher U, Jonas S et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-35.
17. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver trasplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-26.
18. O'Grady JG, Smith HM, Davies SF, Daniels HM, Donaldson PT, Tan KC et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical applications. J Hepatol 1992;14:104-11.
19. Colledan M, Grendele M, Gridelli B, Rossi G, Fassati LR, Ferla G et al. Long-term results after liver transplantation in B and delta hepatitis. Transplant Proc 1989;21:2421-3.
20. Muller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C et al. Liver transplantation in HBs antigen (HbsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991;13:90-6.
21. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP et al. Passive immunoprophylaxis after liver transplantation in HbsAg-positive patients. Lancet 1991;337:813-5.
22. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999;5:491-6.
23. Faust D, Rabenau HF, Allwin R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003;17:254-8.
24. Burbach GJ, Bienzle U, Neuhaus R, Hopf IJ, Metzger WG, Pratschke J et al. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 1997;63:478-80.
25. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde K-H et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998;27:254-63.
26. Pruett T. Indefinite passive immunization after liver transplantation for hepatitis B. Liver Transpl 2000;8:S88-9.
27. Lake JR. Hepatitis B immune globulin for life versus limited use: I favor limited duration of therapy. Liver Transpl 2000;8:S90-1.
28. Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control. J Hepatol 2001;34:943-5.
29. Feray C, Zignego L, Samuel D, Bismuth A, Reynes M, Tiollais P et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. Transplantation 1990;49:1155-8.
30. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-7.
31. Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001;67:45-50.
32. Malkann G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000;69:1403-7.
33. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: Long-term follow up. Transplantation 2000;70:809-15.
34. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32.
35. Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-81.
36. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globuline is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000;6:434-9.
37. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo R, de Man R et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94.
38. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122:264-73.
39. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-13.
40. Perrillo RP, Rakela J, Dienstag J, Levy G, Martin P, Wright T et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999;29:1581-6.
41. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001;7:504-10.
42. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF et al. The polymerase L528M mutation cooperates with nucleotide binding site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001;107:449-55.
43. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M et al. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occuring under HBIG immunoglobulin after liver transplantation. Hepatology 1999;30:244-56.
44. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 2000;6:429-33.
45. Mc Caughan GW, Spencer J, Koorey D, Bowden S, Batholomeusz A, Littlejohn M et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:512-9.
46. Seehofer D, Rayes N, Steinmuller T, Muller AR, Settmacher U, Neuhaus R et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transplant 2001;7:976-82.
47. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M et al. Emergenee and take-over of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild-type after cessation of therapy. Hepatology 1998;27:1711-6.
48. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE et al. Adefovir dipivoxil (ADV) alone or in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis. J Hepatol 2002;36 Suppl 1:6.
49. Lo CM, Fung JT, Lau GK, Cheung ST, Lai CL, Fan ST et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003;37:36-43.
50. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIG) and lamivudine with long-term lamivudine plus HBIG in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811-7.
51. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis 13 reinfection after liver transplantation; possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
52. Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver trasplantation. Transplantation 2003;75:S41-4.
53. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersitz H et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-9.
54. Marzan A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A et al. Prevention of hepatitis B recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-10.
55. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantion. Transpl Infect Dis 2002;4:137-43.
56. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-8.
57. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto I, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999;5:520-5.
58. Starkel P, Cicarelli O, Lerut J, Goubau P, Rahier J, Horsmans Y. Limited lamivudine and long-term hepatitis B immunoglobulin immunoprophylaxis for prevention of hepatitis B recurrence after liver transplantation. Transplantation 2002;15:408-10.
59. Nevens P, Goubau P, van Eyken P, Desmyter J, Desmet V, Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 1993;13:15-9.
60. Wright HI, Gavaler JS, van Theil DH. Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992;53:121-4.
61. Marcellin P, Samuel D, Areias J, Loriot MA, Arulnaden JL, Gigou M et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related endstage liver disease. Hepatology 1994;19:6-12.
62. Hassanein T, Colantoni A, De Maria N, van Thiel DH. Interferon-alpha 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. J Viral Hepat 1996;3:333-40.
63. Seehofer D, Rayes N, Berg T, Neuhaus R, Hopf U, Muller AR et al. Additional interferon-alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report. Transplantation 2000;69:1739-42.
64. Terrault N, Holland C, Ferrell I, Hahn J, Lake J, Roberts J et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 1996;2:132-8.
65. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexa GJ et al. Hepatic histological findings after liver transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
66. Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;49:436-40.
67. Mutimer D, Feraz-Neto BH, Harrison R, O'Donnell K, Shaw J, Cane P et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001;49:860-3.
68. Farrell GC. Clinical potential of emerging new agents in hepatitis B. Drugs 2000;60:701-10.
69. Chin R, Torresi J, Earnest-Silveira L, Trautwein C, Bock T, Manns M et al. Two novel antiviral agents, DAPD and L-FMAU, which are active against wild-type and lamivudine resistant HBV. Hepatology 1999;30 Suppl 4:421A.
70. Payes N, Seehofer D, Bechstein WO, Muller AR, Berg T, Neuhaus R, et al. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin Transplant 1999;13:447-52.
71. Kruger M, Tillmann H, Trautwein C, Bode U, Oldhafer K, Maschek H et al. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl Surg 1996;2:253-62.
72. Singh N, Gayowski T, Wannstedt CF, Wagner MM, Marino IR. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 1997;63:1415-9.
73. Manns MP, Neuhaus P, Atkinson GF, Griffin KE, Barnass S, Vollmar J et al. Famciclovir treatment of hepatitis B infection following liver transplantation. Transpl Infect Dis 2001;3:16-23.
74. Rayes N, Seehofer D, Hopf U, Neuhaus R, Naumann U, Bechstein WO et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001;71:96-101.
75. De Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
76. Chang TT, Hadziyannis S, Cianciara J, Rizzeto M, Schiff E, Pastore G et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology 2002;36 Suppl 4:300A.
77. Shakil AO, Lilly L, Angus P, Gerken G, Thomas N, Jean M et al. Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection. J Hepatol 2002;36 Suppl 1:122.
78. Benhamou Y, Bochet M, Tubiana R, Thibault V, Suffisseau L, Sullivan M et al. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in chronic hepatitis B patient co-infected with HIV. J Hepatol 2002;36 Suppl 1:138.
79. Kulig CC, Trotter JF, Everson GT. Treatment of lamivudine-resistant chronic hepatitis B with tenofovir. Abstracts of Digestive Disease week 2003; May 17-22, Orlando. FL, USA (Abst M2029).
80. Nery J, Lau D, Nery C, Safdar K, Torres M, Neff GW et al. Tenofovir and HBV mutants after liver transplantration. Abstracts of Digestive Disease week 2003; May 17-22, Orlando, FL, USA (Abst. 342).
81. Cooksley H, Chokshi S, Wedemeyer H, Andreone P, Gilson R, Warnes T et al. Hepatitis B virus-specific T-cell reactivity during adefovir (ADV) treatment: a multicentre, controlled study. J Hepatol 2002;36 Suppl 1:7.
82. Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrobial Agents Chemother 2002;46:425-33.
83. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin 1999;103:1635-40.
84. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34.
85. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999;29:1863-9.
86. Hadziyannis S, Tassopolous N, Heathcote E, Chang TT, Kitis G, Rizzetto T et al. A double blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results. J Hepatol 2002;36 Suppl 1:4.
87. Yang H, Westland CE, Delaney WE 4th, Heathcote EJ, Ho V, Fry J et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-73.
88. Yang H, Westland CE, Delaney WE 4th, Gibbs C, Miller M, Fry J et al. Lack of emerging resistance mutations in 467 HbeAg-negative and HbeAg-positive patients with chronic hepatitis B receiving adefovir dipivoxil treatment for 48 weeks. J Hepatol 2002;36 Suppl 1:137.
89. Yang H, Westland CE, Delaney WE 4th, Ho V, Miller MD, Gibbs CS et al. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72-136 weeks. Hepatology 2001;34:316A.
90. Heathcote EJ, Jeffers L, Perillo R, Wright T, Sherman M, Namini H et al. Sustained antiviral response and lack of viral resistance with long-term adefovir dipivoxil (ADV) therapy in chronic HBV infection. J Hepatol 2002;36 Suppl 1:110.
91. Marcellin P, Goodman Z, Chang TT, Lim SG, Tong M, Sievert W et al. Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil. J Hepatol 2002;36 Suppl 1:8.
92. Schiff E, Neuhaus P, Tillmann H, Samuel D, Terrault N, Durand F et al. Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (pot-OLT) patients. J Hepatol 2002;36 Suppl 1:32.
93. Sanchez-Fueyo A, Rimola A, Grande L, Costa I, Mas A, Navasa M et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000;31:496-501.
94. Angelico M, Di Paolo D, Trinito MO, Petrolati A, Araco A, Zazza S et al. Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35:176-81.
95. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC et al. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology 2001;34:372-6.
96. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B replication in vitro. Hepatology 1995;22:36-43.